Molecular Targeted Therapies in Pancreatic Cancer

作者: Edward Kim , Ethan V. Abel , Arunima Ghosh , Diane M. Simeone

DOI: 10.1007/978-1-4614-6549-2_6

关键词:

摘要: Pancreatic cancer, one of the deadliest malignancies, is a complex disease consisting heterogeneous cancer cells with deregulated signaling pathways and myriad microenvironment cells, including infiltrating immune fibroblasts, that impact tumor growth susceptibility to conventional chemotherapy. Understanding drive pancreatic crucial development novel targeted therapies combat disease, which largely refractory therapeutic options. Among these are Hedgehog, NOTCH, Wnt, MET, TGF-β control not only bulk growth, but also self-renewal stem maintenance desmoplastic stroma characteristic disease. In addition altered pathways, many within promote both serve as barrier Here we will discuss how targeting components may increase efficacy it treated.

参考文章(153)
Timothy L. Ratliff, Robin T. Vollmer, Peter A. Humphrey, Xiaopei Zhu, Mark L. Day, Paul E. Swanson, Reza Zarnegar, Hepatocyte growth factor and its receptor (c-MET) in prostatic carcinoma. American Journal of Pathology. ,vol. 147, pp. 386- 396 ,(1995)
Adrian L. Harris, Hypoxia — a key regulatory factor in tumour growth Nature Reviews Cancer. ,vol. 2, pp. 38- 47 ,(2002) , 10.1038/NRC704
Sachin Gupta, Naoko Takebe, Patricia LoRusso, Review: Targeting the Hedgehog pathway in cancer: Therapeutic Advances in Medical Oncology. ,vol. 2, pp. 237- 250 ,(2010) , 10.1177/1758834010366430
M. Lyon, J.A. Deakin, K. Mizuno, T. Nakamura, J.T. Gallagher, Interaction of hepatocyte growth factor with heparan sulfate : elucidation of the major heparan sulfate structural determinants Journal of Biological Chemistry. ,vol. 269, pp. 11216- 11223 ,(1994) , 10.1016/S0021-9258(19)78113-7
Toshiyuki Kusama, Melissa A. Rowland-Goldsmith, Haruhisa Maruyama, Sonia Ralli, Murray Korc, Soluble Type II Transforming Growth Factor-β (TGF-β) Receptor Inhibits TGF-β Signaling in COLO-357 Pancreatic Cancer Cells in Vitro and Attenuates Tumor Formation Clinical Cancer Research. ,vol. 7, pp. 2931- 2940 ,(2001)
Martin Hrabě de Angelis, Urban Lendahl, Helena Edlund, Åsa Apelqvist, Hao Li, Lukas Sommer, Paul Beatus, David J. Anderson, Tasuku Honjo, Notch signalling controls pancreatic cell differentiation Nature. ,vol. 400, pp. 877- 881 ,(1999) , 10.1038/23716
R. H. Hruban, C. Rosty, R. E. Wilentz, M. Tascilar, M. Goggins, C. J. Yeo, S. E. Kern, J. L. Cameron, H. G. Skinner, R. A. Abrams, G. J A Offerhaus, T. Sohn, V. Adsay, The SMAD4 protein and prognosis of pancreatic ductal adenocarcinoma Clinical Cancer Research. ,vol. 7, pp. 4115- 4121 ,(2001)
R. Poulsom, N. R. Lemoine, P. M. Comoglio, M. F. Di Renzo, M. Olivero, Expression of the Met/Hepatocyte Growth Factor Receptor in Human Pancreatic Cancer Cancer Research. ,vol. 55, pp. 1129- 1138 ,(1995)
A. Gossler, J.L. Guenet, D. Simon, M. Hrabe de Angelis, B. Bettenhausen, Transient and restricted expression during mouse embryogenesis of Dll1, a murine gene closely related to Drosophila Delta Development. ,vol. 121, pp. 2407- 2418 ,(1995) , 10.1242/DEV.121.8.2407
M F Di Renzo, S Giordano, M Olivero, A Giacomini, H Porte, S Bottardi, L Mirossay, B Nordlinger, E Chastre, S Bretti, Overexpression and amplification of the Met/HGF receptor gene during the progression of colorectal cancer Clinical Cancer Research. ,vol. 1, pp. 147- 154 ,(1995)